L'Oreal says weight loss drugs are impacting beauty and skin care sales
Summary
L’Oreal says weight loss drugs called GLP-1s have changed how people buy beauty and skin care products. The company is creating products to help with skin issues caused by rapid weight loss, and sales have grown faster than expected.Key Facts
- GLP-1 drugs like Ozempic, Wegovy, and Mounjaro were originally made for diabetes but also cause weight loss by reducing appetite.
- Rapid weight loss can lead to loose skin, especially around the face, though this is not a direct drug effect.
- L’Oreal’s brands SkinCeuticals and Kiehl’s have made products to help with skin sagging linked to weight loss.
- L’Oreal’s sales grew by 7.7% in the three months ending September, beating analyst predictions.
- L’Oreal increased its investment in dermatology company Galderma to 20% in December.
- Galderma makes aesthetic products like Sculptra and Restylane, used to improve skin appearance through injections.
- Both L’Oreal and Galderma are testing treatments for people using GLP-1 drugs who are concerned about changes in their facial skin.
- Surveys show many weight loss drug users notice changes in their facial look after treatment.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
